Innovage Holding Corp. (INNV)
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
$10.75-0.19%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Care FacilitiesSnapshot 2026-09-04
Warn: Management is running behind on a stated commitment.
InnovAge raised its 2026 revenue guidance to about $975 million. Revenue grew from $221 million in 2025-Q4 to $252 million in 2026-Q3. The company hired a new President and COO to improve leadership. Adjusted EBITDA guidance was raised to $90 million, showing better operations.
Operating income is still negative and got worse in 2026-Q3. The company is loss-making and profit margins are weak. Leadership changes have not yet improved financial results.
The price is about 46% above our fair value near $8. Analysts expect 9% revenue growth, which we think is fair.
Breaks if: Adjusted EBITDA falls below $85 million in fiscal 2026
Raise full year fiscal 2026 Adjusted EBITDA guidance reflecting improved operational performance.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The current thesis is intact, supported by strong recent financial performance, but the company is still navigating challenges related to profitability and market conditions.
The market appears to be pricing in a durable premium compared to peers, reflecting a significant expectations gap. However, the valuation is considered unjustified given the company's loss-making status and recent volatility.
Management has been focused on raising revenue and adjusted EBITDA guidance, with recent results showing strong revenue growth. However, operating income has fluctuated, indicating mixed performance and potential risks in the near term.
The long-term thesis hinges on the ability of management to maintain revenue growth and improve profitability while navigating sector trends. Key factors include guidance updates from management and performance of sector bellwethers, which could influence market sentiment.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 3 of last 3 quarters. Adjusted EBITDA guidance was raised from $70M-$75M to $85M-$90M in 2026-Q2. Operating income showed volatility, improving to positive in 2026-Q2 but declining again in 2026-Q3. The trajectory shows mixed delivery with guidance raised but operating income fluctuating.
“We expect to reaffirm our full year fiscal 2026 Adjusted EBITDA guidance as provided on May 5, 2026.”
“We are raising full year fiscal 2026 Adjusted EBITDA guidance to $85M-$90M.”
“The Company expects to reaffirm its full year fiscal 2026 guidance as provided on February 3, 2026.”
Breaks if: Key executive roles remain unfilled or unstable past mid-2026
Complete key executive appointments including President and COO to strengthen leadership team.
Stated in 2 of last 2 quarters. Management completed key leadership appointments including President and COO in 2026-Q2 and new directors in 2026-Q1. These changes reflect active leadership transition efforts with mixed impact on financial results.
“Jennifer Browne appointed as President and Chief Operating Officer.”
“Board appointed Pavithra Mahesh and Sean Traynor as new directors.”
Breaks if: Fiscal 2026 revenue falls below $925 million
Continue to increase fiscal 2026 revenue guidance based on year-to-date performance.
Stated as a priority in 4 of last 4 quarters. Revenue grew from $221.4M in 2025-Q4 to $251.9M in 2026-Q3. Management raised fiscal 2026 revenue guidance from $900M-$950M to $925M-$975M reflecting this growth. The trajectory is delivering consistent upward revisions aligned with revenue growth.
“We expect to reaffirm our full year fiscal year 2026 guidance as provided on May 5, 2026.”
“Based on our performance year to date, we are raising our fiscal 2026 revenue guidance.”
“The Company expects to reaffirm its full year fiscal year 2026 guidance as provided on February 3, 2026.”
“InnovAge is confirming financial guidance for fiscal 2026 revenue between $900M and $950M.”
Overall, INNV's trajectory is shaped by a mix of strong recent performance and ongoing risks. Not investment advice.